Brijesh Baral
Brijesh Baral has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Bishal Baral
Brandeis University
1 shared publication- Fabio R. Farias
Federal University of Parana Curitiba Brazil
1 shared publication Guilherme Grossi Lopes Cançado
Hospital das Clínicas da Universidade Federal de Minas Gerais
1 shared publication- Ivo Queiroz
University of Wisconsin-Madison , Madison , Wisconsin, USA , wisc.edu
1 shared publication Juan Pinilla
School of Medicine, CES University
1 shared publication- Juan Pinilla
CES University School of Medicine, Medellín, Colombia
1 shared publication
Latest Publications
- 16 January 2026
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 61 (3) , 308-316
Safety and efficacy of oral microbiome therapy for the treatment of recurrent Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials
This systematic review and meta-analysis aimed to assess the safety and efficacy of oral microbiome therapy (OMT) for the treatment of recurrent Clostridioides difficile infection (CDI). A comprehensive search was performed in PubMed, Cochrane library, Scopus and Embase. All randomized controlled trials (RCTs) meeting predefined inclusion criteria were included. Statistical analysis was performed using R software. Three RCTs comprising 469 patients were analyzed, of whom 250 (53%) received OMT and 219 (47%) received placebo. OMT significantly reduced CDI recurrence at week 8 compared to placebo (risk ratio [RR] 0.57; 95% confidence interval [CI] 0.33-0.99; p = 0.04). In exploratory efficacy analyses, no significant differences in recurrence were observed between groups when stratified by prior fidaxomicin use (RR 0.36; 95% CI 0.03-4.01; p = 0.40) or vancomycin use (RR 0.68; 95% CI 0.30-1.55; p = 0.35). Similarly, Firmicutes engraftment at week 1 (mean difference [MD] 41.78; 95% CI -10.55 to 94.11; p = 0.12) and week 8 (MD 34.06; 95% CI -2.49 to 70.61; p = 0.07) did not show statistically significant between-group differences. Safety outcomes and adverse events were comparable between OMT and placebo. OMT seems to reduce CDI recurrence at week 8 compared with placebo while demonstrating a comparable safety profile, supporting its role as an effective, well-tolerated therapy for recurrent CDI. New studies are necessary to confirm these findings. The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) under registration number CRD420251022230.
- 16 January 2026
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 61 (3) , 308-316
Safety and efficacy of oral microbiome therapy for the treatment of recurrent Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials
This systematic review and meta-analysis aimed to assess the safety and efficacy of oral microbiome therapy (OMT) for the treatment of recurrent Clostridioides difficile infection (CDI). A comprehensive search was performed in PubMed, Cochrane library, Scopus and Embase. All randomized controlled trials (RCTs) meeting predefined inclusion criteria were included. Statistical analysis was performed using R software. Three RCTs comprising 469 patients were analyzed, of whom 250 (53%) received OMT and 219 (47%) received placebo. OMT significantly reduced CDI recurrence at week 8 compared to placebo (risk ratio [RR] 0.57; 95% confidence interval [CI] 0.33-0.99; p = 0.04). In exploratory efficacy analyses, no significant differences in recurrence were observed between groups when stratified by prior fidaxomicin use (RR 0.36; 95% CI 0.03-4.01; p = 0.40) or vancomycin use (RR 0.68; 95% CI 0.30-1.55; p = 0.35). Similarly, Firmicutes engraftment at week 1 (mean difference [MD] 41.78; 95% CI -10.55 to 94.11; p = 0.12) and week 8 (MD 34.06; 95% CI -2.49 to 70.61; p = 0.07) did not show statistically significant between-group differences. Safety outcomes and adverse events were comparable between OMT and placebo. OMT seems to reduce CDI recurrence at week 8 compared with placebo while demonstrating a comparable safety profile, supporting its role as an effective, well-tolerated therapy for recurrent CDI. New studies are necessary to confirm these findings. The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) under registration number CRD420251022230.
- 24 August 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (4) , 2675-2685
MitraClip Versus Surgery for Secondary Mitral Regurgitation: A Systematic Review and Updated Meta‐Analysis
Background: The optimal management of secondary mitral regurgitation (MR) remains uncertain, with surgical and percutaneous approaches offering alternative treatment strategies. Aim: To compare percutaneous repair with mitral transcatheter edge‐to‐edge repair (M‐TEER) using MitraClip and surgical intervention in patients with secondary MR. Methods: We systematically searched PubMed, Embase, and Cochrane for studies comparing M‐TEER using MitraClip with surgery in secondary MR, reporting outcomes of interest. Risk ratios (RR) with 95% confidence intervals (CI) were pooled using a random‐effects model in R software. Heterogeneity was assessed with I² statistics. Results: A total of 11 studies (two randomized controlled trials and nine observational studies) comprising 1605 patients were included. The mean age was 69 years. Among them, 906 (57.7%) underwent MitraClip. Mean follow‐up was 24.7 months (minimum: 6 months). The rate of MR grade ≤ 2+ at follow‐up was lower in the MitraClip group compared to surgery (RR: 0.86, 95% CI: 0.78 to 0.95, p < 0.01). No significant differences were observed in all‐cause mortality (RR: 1.18, 95% CI: 0.93 to 1.49, p = 0.16), cardiovascular mortality (RR: 1.42, 95% CI: 0.54 to 3.68, p = 0.47), heart failure hospitalizations (RR: 1.55, 95% CI: 0.79 to 3.04, p = 0.20), or NYHA class I/II at follow‐up (RR: 0.92, 95% CI: 0.83 to 1.01, p = 0.08). Conclusion: Although patients undergoing MitraClip exhibited a lower rate of residual MR ≤ 2+ at follow‐up compared to those treated surgically, this did not translate into higher rates of clinical outcomes, including all‐cause mortality, cardiovascular mortality, heart failure hospitalizations, or impaired functional status (NYHA classification).
- 24 August 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (4) , 2675-2685
MitraClip Versus Surgery for Secondary Mitral Regurgitation: A Systematic Review and Updated Meta‐Analysis
Background: The optimal management of secondary mitral regurgitation (MR) remains uncertain, with surgical and percutaneous approaches offering alternative treatment strategies. Aim: To compare percutaneous repair with mitral transcatheter edge‐to‐edge repair (M‐TEER) using MitraClip and surgical intervention in patients with secondary MR. Methods: We systematically searched PubMed, Embase, and Cochrane for studies comparing M‐TEER using MitraClip with surgery in secondary MR, reporting outcomes of interest. Risk ratios (RR) with 95% confidence intervals (CI) were pooled using a random‐effects model in R software. Heterogeneity was assessed with I² statistics. Results: A total of 11 studies (two randomized controlled trials and nine observational studies) comprising 1605 patients were included. The mean age was 69 years. Among them, 906 (57.7%) underwent MitraClip. Mean follow‐up was 24.7 months (minimum: 6 months). The rate of MR grade ≤ 2+ at follow‐up was lower in the MitraClip group compared to surgery (RR: 0.86, 95% CI: 0.78 to 0.95, p < 0.01). No significant differences were observed in all‐cause mortality (RR: 1.18, 95% CI: 0.93 to 1.49, p = 0.16), cardiovascular mortality (RR: 1.42, 95% CI: 0.54 to 3.68, p = 0.47), heart failure hospitalizations (RR: 1.55, 95% CI: 0.79 to 3.04, p = 0.20), or NYHA class I/II at follow‐up (RR: 0.92, 95% CI: 0.83 to 1.01, p = 0.08). Conclusion: Although patients undergoing MitraClip exhibited a lower rate of residual MR ≤ 2+ at follow‐up compared to those treated surgically, this did not translate into higher rates of clinical outcomes, including all‐cause mortality, cardiovascular mortality, heart failure hospitalizations, or impaired functional status (NYHA classification).